Translationally Controlled Tumor Protein in Prostatic Adenocarcinoma: Correlation with Tumor Grading and Treatment-Related Changes

Abstract EN

Prostate cancer is the second leading cause of cancer-related death.

The androgen deprivation therapy is the standard treatment for advanced stages.

Unfortunately, virtually all tumors become resistant to androgen withdrawal.

The progression to castration-resistance is not fully understood, although a recent paper has suggested translationally controlled tumor protein to be implicated in the process.

The present study was designed to investigate the role of this protein in prostate cancer, focusing on the correlation between its expression level with tumor differentiation and response to treatment.

We retrieved 292 prostatic cancer specimens; of these 153 had been treated only by radical prostatectomy and 139 had undergone radical prostatectomy after neoadjuvant treatment with combined androgen blockade therapy.

Non-neoplastic controls were represented by 102 prostatic peripheral zone specimens.

In untreated patients, the expression of the protein, evaluated by RT-qPCR and immunohistochemistry, was significantly higher in tumor specimens than in non-neoplastic control, increasing as Gleason pattern and score progressed.

In treated prostates, the staining was correlated with the response to treatment.

An association between protein expression and the main clinicopathological factors involved in prostate cancer aggressiveness was identified.

These findings suggest that the protein may be a promising prognostic factor and a target for therapy.